Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2003): D’Alessandro V+, Clin Ter 154(3), 207
Infections (16%)
(2002): Poggi MM+, Int J Radiat Oncol Biol Phys 54(3), 670
Injection-site reactions (4%)
Lymphedema
(2000): Brandes A+, Anticancer Drugs 11, 15 (confined to areas
of erysipeloid rash)
Myalgia/Myositis/Myopathy/Myotoxicity (>10%)
(2007): Huang YJ+, Chin Med J (Engl) 120(6), 458
(2002): Voorburg AM+, Lung Cancer 36(2), 203 (with cisplatin)
(2001): Fogarty G+, Lung Cancer 33(2), 299
Nephrotoxicity
(2007): Yamamoto A+, Pancreas 34(3), 378
(2001): Kintzel PE, Drug Saf 24(1), 19
Neurotoxicity
(2007): Huang YJ+, Chin Med J (Engl) 120(6), 458
Pseudolymphoma
(2001): Marucci G+, Br J Dermatol 145(4), 650
GEMFIBROZIL
Trade names: Bolutol; Decrelip; Fibrocit; Gemlipid; Gen-Fibro;
Gevilon Uno; Jezil; Lipur; Lopid (Pfizer); Nu-Gemfibrozil
Indications: Hyperlipidemia
Category: Fibrate; Lipid regulator
Half-life: 1.5 hours
Clinically important, potentially hazardous interactions
with: atorvastatin, bexarotene, cyclosporine, dicumarol,
ezetimibe, fluvastatin, interferon alfa, lovastatin, nicotinic acid,
pioglitazone, pravastatin, repaglinide, rosuvastatin, roxithromycin,
simvastatin, statins, warfarin
Reactions
Skin
Abscess
Acanthosis nigricans
Angioedema
Basal cell carcinoma
Dermatitis (0.4%)
(1988): Todd PA+, Drugs 36, 314
Dermatomyositis (